Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Metacrine Choosing Between Two NASH FXR Agonists It Calls Best-In-Class

Sep 06 2021

• By Joseph Haas

Metacrine is evaluating two FXR agonists to determine which to advance in NASH

Related Content

Terns Raises $87m More For NASH R&D, Including Lilly Equity Purchase

Jan 05 2021

Intercept Commits To Resubmitting NASH NDA, But Analysts See Conflicting Signs

Feb 25 2021

Terns Says Phase IIa Data Show Superior NASH Safety Profile In FXR Class

Jun 14 2021

Intercept's OCA Data Bolster NASH Efficacy, But Pruritus Worries Worsen

Apr 11 2019

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

Jan 27 2020

Intercept’s CRL Just Continues Upheaval In NASH

Jun 29 2020

Gilead’s Bad Luck In NASH Continues With ATLAS Failure

Dec 16 2019

Related Companies

Metacrine, Inc.

Intercept Pharmaceuticals, Inc.

Eli Lilly and Company

Salk Institute for Biological Studies

Gilead Sciences, Inc.

Novartis AG

Terns Pharmaceuticals, Inc.

Additional Topics

Clinical Trials Research & Development Business Strategies Drug Approval Standards Companies Liver & Hepatic BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window